Case report

Effective immunosuppressive therapy in a patient with primary pulmonary hypertension

F Bellotto, P Chiavacci, F Laveder, A Angelini, G Thiene, R Marcolongo

Abstract
The case history is described of a young woman who presented with primary pulmonary hypertension and non-specific inflammatory signs. The patient received prolonged immunosuppressive treatment with low dose methotrexate and prednisone without any vasodilator agent. After one year the pulmonary artery pressure fell from a mean value of 47 mm Hg to 30 mm Hg and there was a corresponding clinical response. This case suggests that, in patients with pulmonary hypertension of unknown origin, immunopathogenetic factors should be sought in order to consider the utility of immunosuppressive therapy.

Keywords: pulmonary hypertension; methotrexate; transforming growth factor β

Primary pulmonary hypertension (PPH) is a rare disease of unknown origin that should be suspected in any young patient who presents with unexplained effort dyspnoea and electrocardiographic signs of right ventricular hypertrophy in the apparent absence of any underlying cause. Pulmonary hypertension clinically and histologically similar to PPH has been described in association with connective tissue diseases and other immunological disorders, also in the absence of any parenchymal lung involvement. Primary forms usually show a rapidly progressive course despite treatment, with a mean survival of 2.5 years.

We describe a patient with PPH who, after treatment with immunosuppressive therapy, showed a clinical improvement.

Case report
A 25 year old woman was admitted in December 1994 because of the recent onset (less than six months) of rest dyspnoea (NYHA class III), cough, cyanosis, hypotension (80/60 mm Hg), tachycardia (120–130 bpm), and congestive heart failure. She had a five year history of recurrent mild temperature elevation, asthenia, myalgia, arthralgia, transient diffuse lymphadenomegaly, neutrophil leukocytosis, and persistent elevation of acute phase reactants, despite anti-inflammatory therapy. Tests for antinuclear (ANA and ENA) and antiphospholipid antibodies, rheumatoid factor, ANCA and other autoantibodies, HIV and other infectious agents were always negative. The patient had never been pregnant nor used appetite suppressants or any other drug potentially able to induce pulmonary hypertension. There were no signs suggestive of connective tissue disease.

Laboratory tests gave the following results: erythrocyte sedimentation rate, 29 mm/h; fibrinogen, 5.32 g/l (normal 2.0–4.0 g/l); antithrombin III 1.42 IU/ml (normal 0.8–1.2); positive indirect antiglobulin test; serum IgE, 1.817 kU/l (normal <200) with negative RAST; serum IgG, 19.30 g/l (normal 8.0–15.0 g/l); serum IgA, 0.32 g/l (normal 1.00–4.90 g/l); ferritin, 1808 ng/l (normal 4–233 ng/l); positivity for HLA-DR4 antigen; moderate increase in peripheral blood CD8+ lymphocytes. Other routine tests were negative or normal.

Lung scans with 99m-technetium labelled albumin macroaggregates and 133-xenon gas and deep vein Doppler ultrasonography of the lower extremities were normal. The electrocardiogram, which had been normal six months earlier, showed signs of right ventricular (RV) pressure overload. The chest radiograph showed normal lung fields and a marked distension of the main pulmonary artery. Echocardiography revealed moderate RV hypertrophy and dilatation, with an RV ejection fraction of 39%, mild tricuspid incompetence, and an estimated pulmonary pressure of 75 mm Hg. Spirometric findings were normal: FEV1 2.43 l (94% of predicted normal) and FVC 2.60 l (119% of predicted normal), FRC 2.08 l, TLC 4.16 l (101% of predicted normal). Arterial blood gas tensions on room air were PaO2 94 mm Hg (12.5 kPa), SaO2 97%, pH 7.41, Pco2 40 mm Hg (5.3 kPa); TCO2 was 23.5 ml CO2/min/mm Hg. Right heart catheterisation showed a pulmonary arterial pressure of 65/30 (mean 47) mm Hg, pulmonary capillary wedge pressure of 3 mm Hg, cardiac output 3.6 l/min, and vascular resistance of 12.2 Wood units. Mean values of pulmonary arterial and capillary wedge pressures and vascular resistance were substantially unaffected by prolonged intravenous infusion of diltiazem (15 mg/kg/min for four hours) or supplemental oxygen.
Immunosuppressive therapy for pulmonary hypertension

= pulmonary artery pressure; R = vascular resistance. methotrexate; ESR = erythrocyte sedimentation rate; PAP = pulmonary arterial pressure; PDN = prednisone; MTX = methotrexate.

Figure 1 Relationship between the clinical course and immunosuppressive treatment. PDN = prednisone; MTX = methotrexate; ESR = erythrocyte sedimentation rate; PAP = pulmonary artery pressure; R = vascular resistance.

Open lung biopsy specimens showed diffuse involvement of small arteries and arterioles, intimal fibrocellular proliferation and severe luminal narrowing; there were no signs of inflammatory, thromboembolic, or pulmonary veno-occlusive disease, suggesting the diagnosis of PPH. Immunofluorescence staining for immunoglobulins, complement, and fibrinogen was negative.

Given the rapid progression of the disease, the lack of any acute reactivity to vasodilator agents, and the suspicion of an immune mediated pathogenetic mechanism because of the persistent signs of systemic inflammation, immunosuppressive therapy with oral prednisone (1.3 mg/kg/day for one month gradually tapering to 5 mg/day over six months) and methotrexate (7.5 mg/week over 36 hours followed by low dose folinic acid, 2.5 mg/week) was administered for one year with the patient’s informed consent.

The patient received only immunosuppressive treatment without any vasodilator or anti-coagulation. She became completely asymptomatic in a few weeks, the inflammatory indices steadily returning to within normal ranges. The patient’s quality of life improved dramatically (NYHA class I), enabling her to perform even some sports. A right heart catheterisation control after 12 months showed a marked reduction in both pulmonary arterial pressure (43/18 mm Hg, mean 30) and vascular resistance (4.36 Wood units) with a cardiac output of 5.5 l/min. The electrocardiographic signs of RV overload were no longer present and RV function appeared normal on echocardiography.

After 30 months methotrexate has been discontinued and the patient, who is still taking prednisone, 5 mg/day, remains well.

Discussion

In this patient immunosuppressive therapy alone produced a significant decrease in pulmonary vascular resistance, steadily reducing the right heart overload and leading to the complete remission of any sign or symptom of pulmonary hypertension. The variable clinical course of PPH and the fact that some patients will remit spontaneously without treatment have been described previously so we cannot theoretically exclude the possibility of a spontaneous remission that occurred coincidentally with immunosuppressive treatment. Nevertheless, there is a close temporal relationship between immunosuppression and disease remission (fig 1).

It has recently been shown that plexogenic arteriopathy may result from deregulated endothelial cell growth. Functionally activated immunocompetent cells surrounding the pulmonary vessels, even in small numbers, may be responsible for the production of local mediators that could favour abnormal endothelial proliferation. In fact, lymphocyte and macrophage released cytokines and growth factors, in addition to the appearance of systemic manifestations, seem also to be involved in pulmonary vascular remodelling. Both the release of immunologically derived factors such as interleukin 1 and transforming growth factor β, and of endothelium derived vasoconstrictive factors (thromboxane and endothelin) together with the impaired production of vasodilator molecules (prostacyclin and nitric oxide), might equally account, at least in some cases, for the pathogenesis of PPH. Thus, pulmonary hypertension and pulmonary vascular remodelling are linked and are mutually self-sustaining.

In patients with NYHA class III or IV and no response to oral calcium channel blockers or a moderate to minimal fall in pulmonary vascular resistance in response to short acting vasodilators, anticoagulation and long term epoprostenol infusions are currently recommended as a possible bridge to lung transplantation. Although immunosuppressive agents are not usually used in these patients, their rational use may be appropriate in some instances. Indeed, by inhibiting the production of pro-inflammatory and proliferative fibrogenic cytokines, and by controlling both immunologically induced intimal hyperplasia and the general immune response, immunosuppression might theoretically arrest and even relieve vascular obstruction and systemic symptoms, interrupting the vicious circle of “cell growth-vasomotor coupling”.

Favourable effects have been anecdotally reported in patients with pulmonary
hypertension associated with autoimmune disorders who have been treated with other immunosuppressive agents such as cyclophosphamide or cyclosporin A. However, the possible efficacy of methotrexate and prednisone in PPH was observed in patients who needed to be confirmed.

Since a recent study reported that a subset of patients with PPH may have an immune mediated disease,1,2 we suggest that even minor signs of immune activation should be carefully evaluated in patients with pulmonary hypertension of unknown origin in order to assess the pathogenetic responsibility of immune factors. We suggest further study of the effect of immunosuppressive treatment in patients with severe and uncontrollable PPH, candidates for lung transplantation, to test the hypothesis of a direct drug induced beneficial effect that is not coincident with spontaneous remission.

number of patients undergoing pneumonectomy compared with lobectomy. We conclude that the two stop service was established there was a significant number of patients with operable disease who were not identified, but that multidisciplinary review of potential operable patients is necessary to prevent inappropriate referrals for surgery.

**Surgical resection rate in lung cancer**

We read with interest the study of Laroche et al. Clearly the system they describe with a multidisciplinary clinic and specialist surgical input will enhance the investigative process and so probably improve the quality of the care of patients presenting to a respiratory service with possible lung cancer. We commend the authors on this.

We do, however, have serious questions as to whether the resection rate of 25% quoted is actually a true reflection on the resection rate for the whole population of patients with lung cancer within the area. In other words, it is essential to know what the absolute denominator was.

A review of registry data in the former Yorkshire region shows that only half the patients with lung cancer present in the “classical” way to a respiratory physician with a prior diagnosis of possible lung cancer. Virtually all patients who do prove operable are found in the half who present in the classical way. If experience is similar in East Anglia, then the denominator should be doubled.

In addition, we are concerned that some patients with advanced chronic obstructive disease or metastatic lung cancer would not have been referred to the clinic by the nine screening chest physicians. Moreover, the review of patients that should cell lung cancers were excluded from the denominator is unclear, and again will improve the apparent resection rate. We note that a number of patients were referred directly specifically for surgery from outside the area, so increasing the numerator.

The authors describe an innovative process for the management of the patient with presumed lung cancer. However, it would be inappropriate to regard the 25% resection rate quoted as a benchmark and a possible audit standard for other lung cancer services, particularly where comorbidity is likely to be higher than in East Anglia.

**Authors’ reply.** We agree with the above signatories that our surgical resection rate of 25% may not reflect the resection rate for the whole population of lung cancer patients within the area. What is certain is that our investigation process immediately led to a significant increase in the overall number of patients being referred for surgical resection from within the referral region, and that the number has continued to rise with the increased number of referrals into the system. We have found problems ourselves in attempting to obtain a true figure for overall resection rates.

Cancer registry data include patients who have not undergone histological confirmation and, as we have found from our service, many patients with presumed lung cancer have in reality alternative diagnoses. However, recognising that virtually all patients who do prove operable present in the classical way to chest physicians, it is important to note that, as mentioned in our paper, resection rates of patients with histologically confirmed lung cancer are still less than 10% in some units.

We would therefore propose that, while continually trying to increase the proportion of patients undergoing histological confirmation, the surgical resection rate of patients with confirmed non-small cell lung cancer would be the most useful benchmark audit indicator for lung cancer services.

**Repeatability of breathlessness measurements in cancer patients**

**Visual analogue scales (VAS) and numerical rating scales are commonly used to assess breathlessness in patients with cancer.** Their repeatability in this situation has not, however, been assessed in a way that allows calculation of the sample size required to design studies with sufficient power to detect a change in breathlessness. We asked 31 patients with breathlessness due to cancer to complete a 100 mm VAS and a numerical rating scale (from 0 to 10) on three occasions, twice on one day one hour apart and then again after a mean (range) of 2 (1–8) days. Patients were asked to rate their breathlessness “right now” and the worst and average severity of breathlessness and the degree of bother it had caused in the preceding 24 hours. Identical words were used to anchor the ends of both scales—for example, “no breathless at all” and “breathlessness as bad as you can imagine”.

Sample sizes were calculated using the following equation:

\[
    n = \frac{\sigma^2}{\beta^2} \left( \frac{Z_{1-\alpha/2} + Z_{1-\beta}}{\Delta} \right)^2 + 2Z_{1-\alpha/2}
\]

where \(\sigma\) is the standard deviation of the difference between tests, \(\Delta\) is a specified reduction in the mean, \(Z\) is the critical values from the Normal distribution to achieve the selected levels of significance and power, \(\alpha\) is level of significance, and \(\beta\) is the power of the test. Table 1 illustrates the sample sizes required to have a reasonable chance of detecting the effect of an intervention that reduced breathlessness scores over a few days in patients with cancer by 25% (\(p \leq 0.05\); power = 90%).

The sample size required, reflecting the repeatability, varies with the particular aspect of breathlessness being measured. The numerical rating scale was a more repeatable measure than the VAS. We conclude that many studies that have examined the effect of an intervention on breathlessness in patients with cancer have not had sufficient power to detect a 25% change following the intervention.

**COPD guidelines**

The BTS guidelines for the management of chronic obstructive pulmonary disease (COPD) state that use of ventilatory support or doxapram should be considered during acute exacerbations of respiratory failure in patients with arterial [H⁺] >55 nmol/l (pH <7.26), which implies that these measures should not be considered when [H⁺] is below this level. The paper cited to support this recommendation reported an uncontrolled prospective study of the application of guideline including this criterion in COPD management, but the figure of [H⁺] >55 nmol/l originated from much earlier work observing that this degree of acidosis predicted increased mortality. The prospective study was not designed to test the hypothesis that only patients with [H⁺] >55 nmol/l should receive respiratory support, and noted, firstly, that clinical judgement led to doxapram being given at lower levels of [H⁺] in 10 of 37
episodes in which it was used and secondly that on retrospective analysis, [H+] >53 nmol/l (pH <7.28) was a better predictor of mortality. ’ The only placebo controlled trial of doxapram for respiratory failure in COPD demonstrated improvement in blood gas parameters in patients with a mean arterial [H+] of 46 nmol/l (pH 7.34), ’ and recent controlled trials of non-invasive ventilation have also shown benefit in subject groups with a mean [H+] below 55 nmol/l. ’ There is a risk that strict application of the BTS guidelines may result in treatment being delayed or withheld from patients with respiratory failure and worsening acidosis on controlled oxygen therapy whose [H+] has not risen to 55 nmol/l, when there is no definitive evidence that such patients cannot benefit from doxapram or ventilatory support. Further trials are clearly needed to define more precisely which patients can benefit from these treatments, but meanwhile can I suggest that this recommendation be reconsidered?

ADAM WHITTLE

Chest Heart and Stroke Scotland Research Fellow, Respiratory Medicine Unit, Western General Hospital, Edinburgh EH4 2XU, UK

3 Hutchinson DCs, Flenley DC, Donald KW. Controlled oxygen therapy in respiratory failure. BMJ 1964;2:1159–60.

AUTHOR’S REPLY

Dr Whittle’s inference from the BTS guidelines was not one that we intended to imply. Lack of comment about the use of doxapram at pH levels greater than 7.26 reflects the paucity of data available and the lack of clinical agreement amongst those producing the guidelines. Usage varies substantially between hospitals and the relative position versus non-invasive ventilation is unclear.

There was agreement that respiratory failure should be actively managed according to the changing acid-base balance and that a pH of less than 7.26 should always be a cause for action. Lesser degrees of acid-base abnormality require clinical interpretation but I would agree that patients with COPD and respiratory failure should not be denied active management.

M G PEARSON

Aintree Hospitals NHS Trust, University Hospital Aintree, Liverpool L9 7AL, UK

BOOK REVIEW


In the preface to the fifth edition of this book, the author’s stated aim is to provide a summary of current respiratory medicine for the medical student, junior doctors preparing for examinations, and general physicians undertaking continuing medical education.

The first chapter deals with the anatomy and physiology of the respiratory system and the second covers history taking and examination. The chapter on pulmonary function tests includes well annotated examples of spirometric tracings and flow-volume loops. The chapter on radiology includes clear diagrams and radiographs. There is a particularly helpful figure which explains the often confused anatomy of the mediastinum as seen on CT scanning.

The following chapters cover the full range of respiratory conditions. They are short but do not stint on detail. Topics covered include up to date opinion on the aetiology and pathology of asthma, advances in the understanding and treatment of cystic fibrosis, the current global epidemic of tuberculosis, current BTS guidelines on the management of asthma and COPD, and a lucid section on the respiratory manifestations of AIDS. Throughout, the text is supplemented by well laid out tables, graphs, and figures from important papers and generally well reproduced radiographs and CT scans, a feature particularly enjoyed were the numerous (and some humorous) line drawings by R A L Brewis himself, including the memorable “blue bloater and pink pulfer” picture on page 117.

In its aim to provide a textbook for undergraduates, junior doctors, and general physicians this work succeeds admirably. As an aid to ward and clinic based learning it has the distinct advantage over its predecessor of fitting into the pocket of a white coat (just). Its attention to detail and clarity will make it a useful work for those undertaking postgraduate examinations and those generalists updating their knowledge of the subject. —AM

NOTICES

10th British Association of Day Surgery

The 10th annual scientific meeting and exhibition of the British Association of Day Surgery (BADS) will be held at Bournemouth International Centre, Bournemouth, UK on 3–5 June 1999. The deadline for abstracts is 31 March 1999. Enquiries regarding registration, abstracts and the exhibition should be addressed to: Kite Communications, The Silk Mill House, 196 Huddersfield Road, Meltham, West Yorkshire HD7 3AP. Tel: 01484 854575. Fax: 01484 854576. e-mail: info@kitecomms.co.uk. Enquiries regarding BADS membership should be addressed to: British Association of Day Surgery, 34–43 Lincoln’s Inn Fields, London WC2A 3PA, UK. CME applied for.

COPD: New Developments and Therapeutic Opportunities

A course on “COPD: New Developments and Therapeutic Opportunities”, suitable for physicians or scientists with an interest in the pharmacology and therapeutics of COPD, organised by Professor Peter Barnes will be held on 14–16 June 1999 at Imperial College, 186 Queen’s Gate, London SW7 2NZ. Further information contact Dr. Paul Barnes, Imperial College, London SW7 2AN. Tel: 0171 589 5213. Fax: 0171 589 5954.

CORRECTION

Respiratory symptoms and home environment in children

In the paper entitled “Respiratory symptoms and home environment in children: a national survey” by M L Burr et al which appeared on pages 27–32 of the January 1999 issue of Thorax, the authors regret that three lines were transposed in table 2. The corrected section of this table relating to housing is shown below.

In addition, the address of Professor D P Strachan was omitted from the address panel on the first page of the paper. His address is: Department of Public Health Sciences, St George’s Hospital Medical School, London SW17 ORE, UK.

<table>
<thead>
<tr>
<th>Environmental factor</th>
<th>Total no.</th>
<th>Wheeze without colds</th>
<th>Wheeze with colds</th>
<th>Rhinitis, itchy eyes</th>
<th>Spring/summer rhinitis</th>
<th>Cough without colds</th>
<th>Phlegm with colds</th>
<th>Phlegm without colds</th>
<th>&gt;3 colds per year</th>
<th>Dry night cough without colds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Housing</td>
<td>Owned</td>
<td>18338</td>
<td>33.5</td>
<td>8.3</td>
<td>21.2</td>
<td>17.9</td>
<td>6.7</td>
<td>27.2</td>
<td>62.0</td>
<td>19.7</td>
</tr>
<tr>
<td></td>
<td>Council</td>
<td>5059</td>
<td>34.4</td>
<td>10.0</td>
<td>20.3</td>
<td>20.6</td>
<td>5.8</td>
<td>36.2</td>
<td>58.3</td>
<td>26.3</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>1013</td>
<td>34.9</td>
<td>9.7</td>
<td>21.5</td>
<td>21.4</td>
<td>7.4</td>
<td>32.7</td>
<td>63.2</td>
<td>23.2</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>983</td>
<td>36.5</td>
<td>11.0</td>
<td>22.5</td>
<td>20.3</td>
<td>5.9</td>
<td>32.8</td>
<td>58.9</td>
<td>22.2</td>
</tr>
</tbody>
</table>

Percentage prevalence of symptoms in children in each environmental group.
Resection rates in lung cancer

ADRIAN PHILLIPS, GILL LAWRENCE and C M LAROCHE

Thorax 1999 54: 374
doi: 10.1136/thx.54.4.374

Updated information and services can be found at:
http://thorax.bmj.com/content/54/4/374.1

These include:

References
This article cites 6 articles, 3 of which you can access for free at:
http://thorax.bmj.com/content/54/4/374.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/